Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR

Ítems similars

• Treatment of EGFR mutation–positive non–small cell lung cancer complicated by Trousseau syndrome with gefitinib followed by osimertinib: a case report
  per: Nonagase, Yoshikane, et al.
  Publicat: (2018)
• Osimertinib administration via nasogastric tube in an EGFR‐T790M‐positive patient with leptomeningeal metastases
  per: Takeda, Takayuki, et al.
  Publicat: (2017)
• First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
  per: Takeda, Masayuki, et al.
  Publicat: (2019)
• Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
  per: Zheng, Lin-Peng, et al.
  Publicat: (2018)
• Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L)
  per: Sakai, Kazuko, et al.
  Publicat: (2020)